561 related articles for article (PubMed ID: 29150198)
1. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Lee JD; Nunes EV; Novo P; Bachrach K; Bailey GL; Bhatt S; Farkas S; Fishman M; Gauthier P; Hodgkins CC; King J; Lindblad R; Liu D; Matthews AG; May J; Peavy KM; Ross S; Salazar D; Schkolnik P; Shmueli-Blumberg D; Stablein D; Subramaniam G; Rotrosen J
Lancet; 2018 Jan; 391(10118):309-318. PubMed ID: 29150198
[TBL] [Abstract][Full Text] [Related]
2. NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.
Lee JD; Nunes EV; Mpa PN; Bailey GL; Brigham GS; Cohen AJ; Fishman M; Ling W; Lindblad R; Shmueli-Blumberg D; Stablein D; May J; Salazar D; Liu D; Rotrosen J
Contemp Clin Trials; 2016 Sep; 50():253-64. PubMed ID: 27521809
[TBL] [Abstract][Full Text] [Related]
3. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
Mitchell MM; Schwartz RP; Choo TH; Pavlicova M; O'Grady KE; Gryczynski J; Stitzer ML; Nunes EV; Rotrosen J
Drug Alcohol Depend; 2021 Feb; 219():108422. PubMed ID: 33352487
[TBL] [Abstract][Full Text] [Related]
4. Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.
Roache JD; Pavlicova M; Campbell A; Choo TH; Peavy M; Kermack AS; Nunes EV; Rotrosen J
Alcohol Clin Exp Res; 2021 Dec; 45(12):2569-2578. PubMed ID: 34698397
[TBL] [Abstract][Full Text] [Related]
5. Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone.
Ruglass LM; Scodes J; Pavlicova M; Campbell ANC; Fitzpatrick S; Barbosa-Leiker C; Burlew K; Greenfield SF; Rotrosen J; Nunes EV
Drug Alcohol Depend; 2019 Dec; 205():107649. PubMed ID: 31704382
[TBL] [Abstract][Full Text] [Related]
6. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
[TBL] [Abstract][Full Text] [Related]
7. Revisiting the X:BOT Naltrexone Clinical Trial Using a Comprehensive Survival Analysis.
Ajazi EM; Dasgupta N; Marshall SW; Monaco J; Howard AG; Preisser JS; Schwartz TA
J Addict Med; 2022 Jul-Aug 01; 16(4):440-446. PubMed ID: 35960214
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
[TBL] [Abstract][Full Text] [Related]
9. Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX).
Kunøe N; Opheim A; Solli KK; Gaulen Z; Sharma-Haase K; Latif ZE; Tanum L
BMC Pharmacol Toxicol; 2016 Apr; 17(1):18. PubMed ID: 27121539
[TBL] [Abstract][Full Text] [Related]
10. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial.
Balter DR; Puglisi LB; Dziura J; Fiellin DA; Howell BA
J Subst Use Addict Treat; 2024 Jun; 164():209438. PubMed ID: 38857827
[TBL] [Abstract][Full Text] [Related]
12. Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults.
Haeny AM; Montgomery L; Burlew AK; Campbell ANC; Scodes J; Pavlicova M; Rotrosen J; Nunes E
Addict Behav; 2020 Nov; 110():106514. PubMed ID: 32619868
[TBL] [Abstract][Full Text] [Related]
13. Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse.
Greiner MG; Shulman M; Choo TH; Scodes J; Pavlicova M; Campbell ANC; Novo P; Fishman M; Lee JD; Rotrosen J; Nunes EV
J Subst Abuse Treat; 2021 Dec; 131():108447. PubMed ID: 34098301
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.
Murphy SM; Jeng PJ; McCollister KE; Leff JA; Jalali A; Shulman M; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
Addiction; 2021 Dec; 116(12):3444-3453. PubMed ID: 33950535
[TBL] [Abstract][Full Text] [Related]
15. Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians.
Randesi M; Rotrosen J; Nunes EV; Lee JD; Novo P; Levran O; Ott J; Pavlicova M; Scodes J; Kreek MJ
Am J Drug Alcohol Abuse; 2020 Nov; 46(6):761-768. PubMed ID: 32851876
[No Abstract] [Full Text] [Related]
16. Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
Comer SD; Mannelli P; Alam D; Douaihy A; Nangia N; Akerman SC; Zavod A; Silverman BL; Sullivan MA
Am J Addict; 2020 Jul; 29(4):313-322. PubMed ID: 32246728
[TBL] [Abstract][Full Text] [Related]
17. Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables.
Rudolph KE; Díaz I; Hejazi NS; van der Laan MJ; Luo SX; Shulman M; Campbell A; Rotrosen J; Nunes EV
Addiction; 2021 Aug; 116(8):2094-2103. PubMed ID: 33340181
[TBL] [Abstract][Full Text] [Related]
18. Patients' perspectives on initiating treatment with extended-release naltrexone (XR-NTX).
Gauthier P; Greco P; Meyers-Ohki S; Desai A; Rotrosen J
J Subst Abuse Treat; 2021 Mar; 122():108183. PubMed ID: 33162260
[TBL] [Abstract][Full Text] [Related]
19. Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone.
Tsui JI; Campbell ANC; Pavlicova M; Choo TH; Lee JD; Cook RR; Shulman M; Nunes EV; Rotrosen J
Drug Alcohol Depend; 2022 Jul; 236():109469. PubMed ID: 35605529
[TBL] [Abstract][Full Text] [Related]
20. Comparison of naltrexone implant and oral buprenorphine-naloxone in the treatment of opiate use disorder.
Erdoğan A; Topcuoğlu M; Coşkun MN; Cinemre B; Kulaksızoğlu B; Kuloğlu MM
Hum Psychopharmacol; 2022 Mar; 37(2):e2813. PubMed ID: 34532895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
